GSK to Acquire Efimosfermin From Boston Pharmaceuticals

Cleary Gottlieb is representing GSK in its acquisition of Boston Pharmaceuticals’ lead asset efimosfermin alfa.

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totaling $800 million.

This transaction is subject to customary conditions.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

Boston Pharmaceuticals is a clinical-stage biopharmaceutical company that leverages an experienced and committed drug development team to advance a portfolio of highly differentiated therapies that may address important unmet medical needs in serious liver diseases. It is a portfolio company of B-Flexion, a private, entrepreneurial investment firm that manages the combined funds and investments associated with the Bertarelli family and also partners with sophisticated capital to meet the shared goal of delivering exceptional value over the generations, while also contributing positively to society.

For more information, please see the press release.